Akero Therapeutics Reports Positive Results from SYMMETRY Study in Recent 8-K Filing

Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding its financial condition and recent clinical study results in its latest 8-K filing with the Securities and Exchange Commission.

In the filing, the company reported that as of December 31, 2024, it anticipates having approximately $800 million in cash, cash equivalents, and marketable securities. While the financial results for this period are yet to be finalized, this figure is subject to change pending the completion of financial statement closing procedures and audits.

Moreover, Akero Therapeutics disclosed a press release entitled “Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—at Week 96 in Phase 2b SYMMETRY Study.” The company shared promising results from the SYMMETRY study, evaluating the lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH).

Among the highlights mentioned were that a significant percentage of patients treated with 50mg EFX experienced reversal of cirrhosis without worsening of MASH compared to the placebo group, as highlighted in both the Completer and Intent to Treat analyses at week 96. The study also indicated favorable tolerability of EFX over the treatment period.

The data showed a substantial doubling of the effect size from weeks 36 to 96 in the 50mg EFX group, emphasizing the benefits of longer treatment. Additionally, a subgroup analysis suggested that the observed reversal of cirrhosis was not solely attributable to GLP-1 therapy.

In terms of financial statements and exhibits, Akero Therapeutics furnished its corporate presentation, detailing its commitment to restoring balance and renewing life through innovative therapies for various diseases.

The company’s forward-looking statements highlighted the potential benefits of EFX and the ongoing clinical studies. However, Akero Therapeutics cautioned that these statements are subject to various risks and uncertainties, as detailed in its filings with the SEC.

All results presented in the filing spoke to the encouraging progress made by Akero Therapeutics, underscoring the potential impact of their product candidate on patients with metabolic dysregulation-associated cirrhosis.

The 8-K filing provided a comprehensive overview of Akero Therapeutics’ recent advancements and the positive outcomes of its SYMMETRY study in the evaluation of EFX, marking a significant milestone in the company’s pursuit of novel therapeutic solutions.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Akero Therapeutics’s 8K filing here.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.